Suppression of well-established tumour xenografts by a hybrid-hybrid monoclonal antibody and vinblastine

The hybrid-hybrid monoclonal antibody 28-19-8 has specificity for the tumour-associated antigen carcinoembryonic antigen and the vinca alkaloids. This bifunctional antibody has been used to target unmodified vinblastine sulphate to well-established MAWI human tumour xenografts implanted in nude mice...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology Immunotherapy 1990-05, Vol.31 (3), p.157-163
Main Authors: SMITH, W, GORE, V. A, BRANDON, D. R, LYNCH, D. N, CRANSTONE, S. A, CORVALAN, J. R. F
Format: Article
Language:English
Subjects:
Adenocarcinoma - immunology
Adenocarcinoma - pathology
Adenocarcinoma - therapy
Animals
Antibodies, Monoclonal - isolation & purification
Antibodies, Monoclonal - therapeutic use
Antineoplastic agents
Biological and medical sciences
Carcinoembryonic Antigen - immunology
Humans
Immunization Schedule
Immunoenzyme Techniques
Immunotherapy
Immunotoxins - administration & dosage
Medical sciences
Mice
Mice, Nude
Neoplasm Transplantation
Original
Pharmacology. Drug treatments
Vinblastine - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The hybrid-hybrid monoclonal antibody 28-19-8 has specificity for the tumour-associated antigen carcinoembryonic antigen and the vinca alkaloids. This bifunctional antibody has been used to target unmodified vinblastine sulphate to well-established MAWI human tumour xenografts implanted in nude mice. The highly significant suppression of tumour growth achieved throughout treatment has also been sustained for over 2 months after the withdrawal of treatment. Histological examination of excised tumours from treated animals has shown profound changes in their morphology when compared with tumours from control animals. Cells in tumours that had started to grow again after withdrawal of therapy were shown still to express carcinoembryonic antigen, the target antigen recognised by the bispecific antibody.
ISSN:0340-7004
1432-0851
DOI:10.1007/BF01744730